NCT00378209 - Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2016

Conditions

Multiple Myeloma

Interventions

DRUG

Bortezomib

Given intravenously on days 1,4,8 and 11 of a 21-day cycle for a minimum of 8 cycles.

DRUG

Lenalidomide

Taken orally once a day for 2 weeks (days 1-14) of a 21-day cycle for a minimum of 8 cycles

DRUG

Dexamethasone

Taken orally on days 1,2,4,5,8,9,11,and 12 of a 21-day cycle for a minimum of 8 cycles

Trial Locations (2)

Massachusetts General Hospital, Boston

Dana-Farber Cancer Institute, Boston